T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy
Journal of Extracellular Vesicles · 2023
DOI: 10.1002/jev2.12350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2023. Verfasst von Aida S Hansen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Health, Aarhus Midtjylland, Denmark. Hauptthemen laut MEDLINE: Extracellular Vesicles, Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danmarks Frie Forskningsfond, Kræftens Bekæmpelse, Lundbeckfonden.
Abstract (Originalsprache)
A key phenomenon in cancer is the establishment of a highly immunosuppressive tumour microenvironment (TME). Despite advances in immunotherapy, where the purpose is to induce tumour recognition and hence hereof tumour eradication, the majority of patients applicable for such treatment still fail to respond. It has been suggested that high immunological activity in the tumour is essential for achieving effective response to immunotherapy, which therefore have led to exploration of strategies that triggers inflammatory pathways. Here activation of the stimulator of interferon genes (STING) signalling pathway has been considered an attractive target, as it is a potent trigger of pro‐inflammatory cytokines and types I and III interferons. However, immunotherapy combined with targeted STING agonists has not yielded sustained clinical remission in humans. This suggests a need for exploring novel adjuvants to improve the innate immunological efficacy. Here, we demonstrate that extracellular vesicles (EVs), derived from activated CD4 + T cells (T‐EVs), sensitizes macrophages to elevate STING activation, mediated by IFNγ carried on the T‐EVs. Our work support that T‐EVs can disrupt the immune suppressive environment in the tumour by reprogramming macrophages to a pro‐inflammatory phenotype, and priming them for a robust immune response towards STING activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Aarhus University, Health, Aarhus Midtjylland, Denmark.
- Department of Clinical Medicine, Center of Functionally Integrative Neuroscience, Aarhus University, Aarhus Midtjylland, Denmark.
- Interdiciplinary Nanoscience Center - iNANO, Aarhus University, Aarhus Midtjylland, Denmark.
- Department of Forensic Medicine, Aarhus University, Aarhus Midtjylland, Denmark.
ORCID-Profile: Martin R Jakobsen
Förderung
- Danmarks Frie Forskningsfond
- Kræftens Bekæmpelse
- Lundbeckfonden
- Gilead Foundation
- Novo Nordisk Fonden
Zitieren
APA
Hansen, A. S., Jensen, L. S., Gammelgaard, K. R., Ryttersgaard, K. G., Krapp, C., Just, J., Jønsson, K. L., Jensen, P. B., Boesen, T., Johansen, M., Etzerodt, A., Deleuran, B. W., & Jakobsen, M. R. (2023). T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12350
Vancouver
Hansen AS, Jensen LS, Gammelgaard KR, Ryttersgaard KG, Krapp C, Just J, et al. T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy. Journal of Extracellular Vesicles. 2023. doi:10.1002/jev2.12350
BibTeX
@article{Hansen2023,
author = {Hansen, Aida S and Jensen, Lea S and Gammelgaard, Kristine R and Ryttersgaard, Kristoffer G and Krapp, Christian and Just, Jesper and Jønsson, Kasper L and Jensen, Pia B and Boesen, Thomas and Johansen, Mogens and Etzerodt, Anders and Deleuran, Bent W and Jakobsen, Martin R},
title = {T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy},
journal = {Journal of Extracellular Vesicles},
year = {2023},
doi = {10.1002/jev2.12350}
}
EUVIMED